{"transactions":[{"id":919130,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:13:46.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":31244,"price":1.39,"value":43429.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025."},{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025."}],"balance_after":561750,"source":{"system":"sec-edgar","filing":"0001661887-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000166188726000002/primarydocument.xml","form_type":"4"}},{"id":919129,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:13:46.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":53585,"price":1.39,"value":74483.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024."}],"balance_after":592994,"source":{"system":"sec-edgar","filing":"0001661887-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000166188726000002/primarydocument.xml","form_type":"4"}},{"id":921243,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-03T21:42:00.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":320000,"derivative":{"exercise_price":1.41,"expiration_date":"2036-01-30","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001661887-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000166188726000001/primarydocument.xml","form_type":"4"}},{"id":921242,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:42:00.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":204000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":646579,"source":{"system":"sec-edgar","filing":"0001661887-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000166188726000001/primarydocument.xml","form_type":"4"}},{"id":1283953,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2025-02-04T22:51:42.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":292300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":292300,"derivative":{"exercise_price":2.24,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":292300},"source":{"system":"sec-edgar","filing":"0001562180-25-000914","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000914/primarydocument.xml","form_type":"4"}},{"id":1283952,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:51:42.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":55621,"price":2.1,"value":116804.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024."},{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2024."}],"balance_after":442579,"source":{"system":"sec-edgar","filing":"0001562180-25-000914","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000914/primarydocument.xml","form_type":"4"}},{"id":1283951,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:51:42.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":194900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":498200,"source":{"system":"sec-edgar","filing":"0001562180-25-000914","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000914/primarydocument.xml","form_type":"4"}},{"id":1660941,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2024-02-02T21:11:51.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":454950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":454950,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":454950},"source":{"system":"sec-edgar","filing":"0001562180-24-000983","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000983/primarydocument.xml","form_type":"4"}},{"id":1660940,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-02T21:11:51.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":303300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":303300,"source":{"system":"sec-edgar","filing":"0001562180-24-000983","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000983/primarydocument.xml","form_type":"4"}},{"id":3616336,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-05T18:03:04.000Z","date":"2019-03-02","kind":"tax_withholding","acquired":false,"shares":982,"price":14.76,"value":14494.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on March 2, 2019."}],"balance_after":84805,"source":{"system":"sec-edgar","filing":"0000792977-19-000044","document":"wf-form4_155182696960170.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000044/wf-form4_155182696960170.xml","form_type":"4"}},{"id":3630274,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-27T18:23:08.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter."}],"balance_after":25000,"derivative":{"exercise_price":15.51,"expiration_date":"2029-02-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000792977-19-000027","document":"wf-form4_155130977417748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000027/wf-form4_155130977417748.xml","form_type":"4"}},{"id":3630273,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-27T18:23:08.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award (\"Target Award\"); however, the amount that vests could range from zero to 150% of the Target Award."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":85787,"source":{"system":"sec-edgar","filing":"0000792977-19-000027","document":"wf-form4_155130977417748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000027/wf-form4_155130977417748.xml","form_type":"4"}},{"id":3630272,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-27T18:23:08.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the \"Plan\") that will vest in three equal annual installments with the first installment vesting on February 25, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":73787,"source":{"system":"sec-edgar","filing":"0000792977-19-000027","document":"wf-form4_155130977417748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000027/wf-form4_155130977417748.xml","form_type":"4"}},{"id":3634183,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-26T17:46:49.000Z","date":"2019-02-23","kind":"tax_withholding","acquired":false,"shares":982,"price":15.51,"value":15230.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on February 23, 2019."}],"balance_after":61787,"source":{"system":"sec-edgar","filing":"0000792977-19-000023","document":"wf-form4_155122119573585.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000023/wf-form4_155122119573585.xml","form_type":"4"}},{"id":3701285,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:13:58.000Z","date":"2019-01-04","kind":"tax_withholding","acquired":false,"shares":3555,"price":16.19,"value":57555.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,669 restricted stock units on January 4, 2019."}],"balance_after":62769,"source":{"system":"sec-edgar","filing":"0000792977-19-000005","document":"wf-form4_154698202175358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000005/wf-form4_154698202175358.xml","form_type":"4"}},{"id":4012802,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-06T19:21:53.000Z","date":"2018-03-02","kind":"grant","acquired":true,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter."}],"balance_after":24000,"derivative":{"exercise_price":21,"expiration_date":"2028-03-02","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001179110-18-003693","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911018003693/edgar.xml","form_type":"4"}},{"id":4012801,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-06T19:21:53.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":4193,"price":21,"value":88053.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,666 RSUs on January 4, 2018 and 3,333 RSUs on February 23, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 4,193 shares were withheld to satisfy the reporting person's applicable tax obligations."}],"balance_after":66324,"source":{"system":"sec-edgar","filing":"0001179110-18-003693","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911018003693/edgar.xml","form_type":"4"}},{"id":4012800,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-06T19:21:53.000Z","date":"2018-03-02","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered  pursuant to the award (\"Target Award\"); however, the amount that vests could range from zero to 150% of the Target Award."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":70517,"source":{"system":"sec-edgar","filing":"0001179110-18-003693","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911018003693/edgar.xml","form_type":"4"}},{"id":4012799,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-06T19:21:53.000Z","date":"2018-03-02","kind":"grant","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the \"Plan\") and will vest in three equal annual installments with the first installment vesting on March 2, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":58517,"source":{"system":"sec-edgar","filing":"0001179110-18-003693","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911018003693/edgar.xml","form_type":"4"}},{"id":4327362,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-05-10T16:42:24.000Z","date":"2017-05-08","kind":"tax_withholding","acquired":false,"shares":3483,"price":18.55,"value":64609.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,665 restricted stock units (\"RSUs\") on January 4, 2017. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the \"Issuer\"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until May 8, 2017, at which time 3,483 shares were withheld to satisfy the reporting person's applicable tax obligations."}],"balance_after":48517,"source":{"system":"sec-edgar","filing":"0001179110-17-006983","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017006983/edgar.xml","form_type":"4"}},{"id":4423061,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-27T19:00:06.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter."}],"balance_after":25000,"derivative":{"exercise_price":23.75,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-17-003321","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003321/edgar.xml","form_type":"4"}},{"id":4423060,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-02-27T19:00:06.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered  pursuant to the award (\"Target Award\"); however, the amount that vests could range from zero to 150% of the Target Award."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":52000,"source":{"system":"sec-edgar","filing":"0001179110-17-003321","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003321/edgar.xml","form_type":"4"}},{"id":4423059,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":67722,"kind":"person","name":"Grund Nicholas","position":1,"cik":"0001661887","reported_name":"Grund Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-02-27T19:00:06.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the \"Plan\") and will vest in three equal annual installments with the first installment vesting on February 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":42000,"source":{"system":"sec-edgar","filing":"0001179110-17-003321","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003321/edgar.xml","form_type":"4"}}]}